NEW CASTLE, Del., Nov. 4, 2025 /PRNewswire/ -- IgniteData, a leader in intelligent clinical trial data automation, today announced the final close of its oversubscribed Series A funding round. This close brings the total capital raised in the round to $11M, fueling IgniteData's expansion of its global research site network, advancement of its flagship product, Archer, and acceleration of innovation in generative AI–powered data automation. IgniteData's Archer platform enables the seamless transf

WASHINGTON, Nov. 4, 2025 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), the largest U.S. non-profit leading Duchenne and Becker muscular dystrophy care, research, and advocacy efforts, and MyoGene Bio (MyoGene) are excited to announce that PPMD has provided $400,000 in funding to MyoGene through PPMD Venture Pathways, the organization's venture-philanthropy initiative that provides industry funding to accelerate therapeutic development for Duchenne and Becker. This funding commitment

Renowned life sciences investor and entrepreneur to bring scientific and strategic expertise to Keebeck's advisory team CHICAGO and BOSTON, Nov. 4, 2025 /PRNewswire/ -- Keebeck Wealth Management, an independent advisory firm serving entrepreneurs and multi-generational families, today announced that Thomas J. Cahill III, M.D., Ph.D., founder and managing partner of Newpath Partners, has joined its Advisory Board. Dr. Cahill is the founder and managing partner of Newpath Partners, a life sciences

At ObesityWeek 2025, new data show overwhelming public support for ensuring that all medications are evaluated and labeled for safety and efficacy in people with obesity. ATLANTA, Nov. 4, 2025 /PRNewswire/ -- New research presented today at ObesityWeek 2025, the world's leading international conference on obesity science and care, shows that people with obesity overwhelmingly expect the U.S. Food and Drug Administration (FDA) and pharmaceutical companies to close critical gaps in how medication

PAMAF™ technology delivers near-complete ion utilization, enabling deeper proteome coverage and improved PTM and proteoform analysis CHADDS FORD, Pa., Nov. 4, 2025 /PRNewswire/ -- MOBILion Systems, Inc., a leader in separation science innovation, announced today its participation in the 24th Annual Human Proteome Organization (HUPO) World Congress, taking place November 9–13, 2025, in Toronto, Canada. MOBILion's Chief Technology Officer, Daniel DeBord, Ph.D., will present new findings on Para

Novo Nordisk Amended Proposal Values Metsera at up to $ 86.20 per Share, a Total of Approximately $ 10.0 Billion Superior to Revised Pfizer Proposal that Valued Metsera at up to $ 70.00 per Share, a Total of Approximately $ 8.1 Billion Pursuant to Pfizer Merger Agreement, Metsera and Pfizer May Negotiate Potential Adjustments for Two Business Days Pfizer Merger Agreement Remains in Effect; No Action Required by Metsera Shareholders NEW YORK, Nov. 4, 2025 /PRNewswire/ -- Metsera, Inc.

RALEIGH, N.C. and TEL-AVIV, Israel, Nov. 4, 2025 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the New York Supreme Court's summary judgment in favor of RedHill against Kukbo Co. Ltd ("Kukbo") is now final and eligible for enforcement and foreign recognition, with no further appeal permissible following expiry of the appeal period. The Court has awarded more than $10.5 million in total to RedHill, c

Studies presented at Obesity Week 2025 validate the test's ability to predict weight-loss response to GLP-1 drugs like semaglutide, including in diverse patient populations and post-bariatric surgery patients. Phenomix's MyPhenome test continues to demonstrate predictive accuracy in identifying which patients are most likely to respond to GLP-1 therapies such as semaglutide. Studies presented at Obesity Week show MyPhenome performs consistently across different patient populations, including

Clinical trial data demonstrates how Bio-Techne's spatial biology technology and Nucleai's AI-powered multimodal platforms can identify predictive biomarkers in immunotherapy and targeted therapy-treated melanoma patients. Bio-Techne's COMET™ platform and Nucleai's multimodal spatial operating system profiled 42 biopsies, revealing immune cell interactions linked to clinical outcomes. Study selected by the scientific committee as one of the top 150 abstracts from over 1,200 submissions at SITC

Breakthrough's One Helix is a Purpose-Built, BREEAM Outstanding Building within Amsterdam University Medical Center AMSTERDAM, Nov. 4, 2025 /PRNewswire/ -- Breakthrough Properties, a premier global life science real estate developer, today announced the completion of One Helix, a fully-leased, state-of-the-art research facility within the campus of the Amsterdam University Medical Center (Amsterdam UMC). Continue Reading One Helix - Breakthrough Properties Breakthrough, a joint venture of